Reviva Pharmaceuticals Holdings, Inc. has announced significant advancements regarding their clinical-stage drug candidate, brilaroxazine, which targets multiple neuropsychiatric and inflammatory conditions. The upcoming fireside chat featuring CEO Laxminarayan Bhat, PhD, on April 27, 2026, will delve into the latest clinical data and regulatory milestones for brilaroxazine, highlighting its promising efficacy and safety profile.

Brilaroxazine has demonstrated statistically significant reductions in schizophrenia symptoms in the Phase 3 RECOVER trial, achieving all primary and secondary endpoints. Notably, the drug reduced key proinflammatory cytokines linked to schizophrenia and comorbid inflammatory conditions within just four weeks, while maintaining a side effect profile comparable to placebo. Furthermore, a drug-drug interaction study confirmed no clinically significant effects when brilaroxazine was combined with CYP3A4 inhibitors, reinforcing its therapeutic potential. Reviva’s plans to explore brilaroxazine’s application in other neuropsychiatric disorders, such as bipolar disorder and major depressive disorder, alongside its promising nonclinical activity in inflammatory diseases like pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), underscore its versatility.

The implications of these findings are substantial for the field of longevity science and healthspan research. Brilaroxazine’s dual action on both neuropsychiatric and inflammatory pathways could catalyze a paradigm shift in how we approach the treatment of age-related diseases. The Orphan Drug Designation granted by the FDA for PAH and IPF further accelerates its development timeline, potentially expediting the introduction of effective therapies for conditions that significantly impact longevity and quality of life. As Reviva continues to advance brilaroxazine through clinical trials, its outcomes may redefine therapeutic strategies in managing complex age-associated diseases.

Source: globenewswire.com